Ken Griffin Takeda Pharmaceutical CO LTD Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$13.0 - $15.08 $10.8 Million - $12.5 Million	831,200 Added 96.18%	1,695,400 $24.1 Million
Q2 2024 Aug 14, 2024	SELL	$12.6 - $13.67 $11.3 Million - $12.3 Million	-897,700 Reduced 50.95%	864,200 $11.2 Million
Q1 2024 May 15, 2024	BUY	$13.89 - $15.04 $11.3 Million - $12.2 Million	813,600 Added 85.8%	1,761,900 $24.5 Million
Q4 2023 Feb 14, 2024	SELL	$13.36 - $15.43 $73,480 - $84,865	-5,500 Reduced 0.58%	948,300 $13.5 Million
Q3 2023 Nov 14, 2023	BUY	$15.03 - $16.32 $13.2 Million - $14.4 Million	879,900 Added 1190.66%	953,800 $14.8 Million
Q2 2023 Aug 14, 2023	SELL	$15.57 - $17.11 $683,523 - $751,129	-43,900 Reduced 37.27%	73,900 $1.16 Million
Q1 2023 May 15, 2023	SELL	$15.28 - $16.48 $1.34 Million - $1.44 Million	-87,500 Reduced 42.62%	117,800 $1.94 Million
Q4 2022 Feb 14, 2023	BUY	$12.42 - $15.62 $552,690 - $695,090	44,500 Added 27.67%	205,300 $3.2 Million
Q3 2022 Nov 14, 2022	SELL	$12.8 - $28.65 $198,400 - $444,075	-15,500 Reduced 8.79%	160,800 $2.09 Million

337

73.8M

1.96M

165K

Ticker TAK
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 3,109,050,112
Market Cap $41.8B
Description
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.